[–] 3 points 2 hours ago (2 children)

I tried to find the report button in the web interface to see if it was the same, but failed.

It is a part of the instance Lemmy.world Terms of Service though:

5.1 Community Manipulation
Do not engage in content manipulation such as posting spam content, vote manipulation through using several user accounts or consistently down-voting a user. Vote for the content, not for the person.
You must also not vote on content posted by other accounts under your control, with the exception of bot accounts, which may receive at most one vote per submission from non-bot accounts under your control.

  • source
  • parent
  • context
  • [–] 2 points 2 days ago (2 children)

    My understanding is, you aren’t “trespassing” in publicly accessible areas, until you’ve been told to leave and refused^*^

    ^*^^Of^ ^course^ ^it^ ^varies^ ^from^ ^jurisdiction^ ^to^ ^jurisdiction,^ ^but^ ^generally^ ^in^ ^the^ ^U.S.^

  • source
  • parent
  • context
  • [–] 5 points 1 week ago

    That was fucking weird. I watched the video first then, reading the article

    I was shocked:

    What was your first thought after watching that video? If you were craving a cigarette, you’re not alone.

    Yes! What?!? How was I not alone in this?

    But social media users have spotted something weird. “The typeface looks very similar to Marlboro,”

    What?!? No!

    Thanks to my grandmother my mind when straight to:

    https://en.wikipedia.org/wiki/More_(cigarette)

  • source
  •  

    Apple on Friday accused OpenAI of stealing secrets about products still in development, setting up a legal face-off between two of the world’s biggest tech companies.

    In a lawsuit filed in U.S. District Court for the Northern District of California, the consumer tech giant said that OpenAI, a leader in artificial intelligence that has a new hardware business, had asked job candidates from Apple to share details about secret projects and to bring device components and prototypes to their interviews.

    Apple also accused an OpenAI employee of downloading internal documents from a laptop owned by the iPhone maker.

    OpenAI used the confidential information to approach Apple’s manufacturing partners, including asking one partner to demonstrate Apple’s technique for finishing metal on its devices, the lawsuit says.

     

    Apple on Friday accused OpenAI of stealing secrets about products still in development, setting up a legal face-off between two of the world’s biggest tech companies.

    In a lawsuit filed in U.S. District Court for the Northern District of California, the consumer tech giant said that OpenAI, a leader in artificial intelligence that has a new hardware business, had asked job candidates from Apple to share details about secret projects and to bring device components and prototypes to their interviews.

    Apple also accused an OpenAI employee of downloading internal documents from a laptop owned by the iPhone maker.

    OpenAI used the confidential information to approach Apple’s manufacturing partners, including asking one partner to demonstrate Apple’s technique for finishing metal on its devices, the lawsuit says.

     

    In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly’s powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration’s “compassionate use” program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News.

    Lilly’s retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery.

    Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods.

    But according to a barebones public notice and Stat’s sources, a single person has been granted early access through the expanded access, aka “compassionate use” pathway, which is typically used to grant access to patients with a “serious or immediately life-threatening disease or condition” and who are not able to enroll in a clinical trial, often because they are too ill.

    The access request was first made in April, when the person was 79 years old (Trump turned 80 on June 14). It was made by a senior clinician at the National Institutes of Health named Ranganath Muniyappa, who requested it on behalf of a patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension, which is high blood pressure in the lungs. Sources told Stat this patient had spent a year on tirzepatide, a drug that targets the GLP-1 and GIP hormones. But the patient had achieved only moderate weight loss on the drug.

    view more: next ›